On Tuesday, Koninklijke Philips N.V. (NYSE:PHG) issued a correction related to the Software Version used in Trilogy Evo, Trilogy EV300, Trilogy Evo O2, and Trilogy Evo Universal ventilators to resolve safety issues that may affect the device’s ability to support patient breathing.
The FDA announcement states that this recall involves correcting devices and does not involve removing them. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without correction.
Also Read: Philips Backs Annual Guidance On Higher Q2 ...
